ALR Technologies SG Ltd. files as a foreign private issuer, and its regulatory documents describe a Singapore-based diabetes management company with ordinary shares traded under ALRTF. The filing record includes Form 6-K current reports, interim consolidated financial statements, management discussion and analysis, controls and procedures, risk factors, legal proceedings, market-risk disclosure, and exhibits tied to company announcements.
Company-specific disclosures cover the GluCurve Pet CGM business, diabetes data-management technology, operating losses and shareholders’ deficit, ordinary-share capital structure, and warrant modifications. The filings also document board and executive-related warrant holdings where those securities are amended or reported in material-event filings.
ALR Technologies SG Ltd. reports a deepening loss and severe liquidity strain for the six months ended June 30, 2025. Net loss widened to about $10,770,000 from $6,028,000, mainly because interest expense soared to $9,367,270, including $8,187,123 of non-cash share-based compensation from modifying warrants held by the CEO and VP. Core operating expenses actually fell 46% to roughly $1,139,000 as product development, professional, and administrative costs decreased.
The balance sheet is highly stressed. Current liabilities were $38,368,906 versus total assets of only $31,002, leaving a working capital deficit of about $38,338,000 and shareholders’ deficit of $38,337,904. The company had cash of just $1,738 and relies heavily on related-party funding, including $21,164,886 of lines of credit and a $3,822,081 loan. Management discloses substantial doubt about its ability to continue as a going concern, with $11,222,000 of promissory notes and related interest in default and prior default judgments outstanding.
ALR Technologies SG Ltd. filed a report as a foreign private issuer to share a recent company announcement. The filing states that on December 8, 2025, the company issued a press release, which is attached to the report as Exhibit 99.1.
The press release announced the relaunch of the company’s GluCurve Pet CGM, a continuous glucose monitoring product for pets. This report mainly serves to make that product update publicly available to investors through the SEC’s disclosure system.